Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Nvidia dives deeper into medtech, cancer research with Droplet Biosciences
Nvidia dives deeper into medtech, cancer research with Droplet Biosciences
ARPA-H launches $158M effort to aid first-ever lymphatic system medicines
ARPA-H launches $158M effort to aid first-ever lymphatic system medicines
Bayer tosses 1 Pompe gene therapy from $2B AskBio buyout to focus on alternative option
Bayer tosses 1 Pompe gene therapy from $2B AskBio buyout to focus on alternative option
UK invests $64M to expand clinical trial access to underserved communities
UK invests $64M to expand clinical trial access to underserved communities
Ono’s Deciphera drops early-stage solid tumor drug for strategic reasons
Ono’s Deciphera drops early-stage solid tumor drug for strategic reasons
Teva bags $400M deal with Blackstone to fund Sanofi-partnered IBD drug
Teva bags $400M deal with Blackstone to fund Sanofi-partnered IBD drug
Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset
Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset
New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program
New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program
Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
FDA details rationale for rejecting rare disease gene therapy from Regenxbio
FDA details rationale for rejecting rare disease gene therapy from Regenxbio
Biohaven reduces scope of R&D cutbacks as pipeline progresses
Biohaven reduces scope of R&D cutbacks as pipeline progresses
MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit
MindMaze seeks 'strategic alternatives,' eyes US expansion as 2 board members exit
Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug
Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug
AI musculoskeletal imaging medtechs Medimaps and Radiobotics pen merger deal
AI musculoskeletal imaging medtechs Medimaps and Radiobotics pen merger deal
GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels
GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels
HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic
HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic
Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout
Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout
TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio
TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio